0.4283
price down icon1.77%   -0.0077
after-market After Hours: .44 0.0117 +2.73%
loading
Nextcure Inc stock is traded at $0.4283, with a volume of 116.20K. It is down -1.77% in the last 24 hours and down -10.83% over the past month. NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$0.436
Open:
$0.4347
24h Volume:
116.20K
Relative Volume:
0.49
Market Cap:
$17.26M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-0.2049
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
-8.11%
1M Performance:
-10.83%
6M Performance:
-47.90%
1Y Performance:
-71.45%
1-Day Range:
Value
$0.42
$0.4535
1-Week Range:
Value
$0.42
$0.4919
52-Week Range:
Value
$0.224
$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Name
Name
Nextcure Inc
Name
Phone
240-399-4900
Name
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Name
Employee
43
Name
Twitter
@nextcureinc
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
NXTC's Discussions on Twitter

Compare NXTC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NXTC
Nextcure Inc
0.4283 17.26M 0 -58.52M -45.03M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-04-22 Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-22 Initiated Ladenburg Thalmann Buy
Mar-05-21 Upgrade Truist Hold → Buy
Jan-15-21 Downgrade BofA Securities Neutral → Underperform
Jul-16-20 Upgrade The Benchmark Company Hold → Buy
Jul-13-20 Downgrade ROTH Capital Buy → Neutral
Jul-13-20 Downgrade SunTrust Buy → Hold
Jun-01-20 Downgrade BofA/Merrill Buy → Neutral
Jun-01-20 Downgrade The Benchmark Company Buy → Hold
May-26-20 Initiated JMP Securities Mkt Outperform
Mar-24-20 Initiated The Benchmark Company Buy
Mar-02-20 Initiated ROTH Capital Buy
Jan-13-20 Initiated SunTrust Buy
Dec-05-19 Initiated Needham Buy
Nov-26-19 Initiated BTIG Research Buy
Jul-09-19 Initiated BofA/Merrill Buy
Jun-03-19 Initiated Morgan Stanley Overweight
Jun-03-19 Initiated Piper Jaffray Overweight
View All

Nextcure Inc Stock (NXTC) Latest News

pulisher
Jun 17, 2025

Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter

Jun 17, 2025
pulisher
Jun 17, 2025

NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Is Lucid Stock a Millionaire-Maker? - The Globe and Mail

Jun 16, 2025
pulisher
Jun 12, 2025

JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail

Jun 11, 2025
pulisher
Jun 10, 2025

COIN Outpaces Industry in 3 Months: Time to Buy the Stock? - The Globe and Mail

Jun 10, 2025
pulisher
Jun 05, 2025

Power Corporation's President and Chief Executive Officer R. Jeffrey Orr to speak at the Scotiabank Financials Summit - The Globe and Mail

Jun 05, 2025
pulisher
Jun 05, 2025

Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews

Jun 05, 2025
pulisher
Jun 05, 2025

Best Dollar Store Stock to Buy: Dollar Tree or Dollar General? - The Globe and Mail

Jun 05, 2025
pulisher
Jun 02, 2025

2 No-Brainer Growth Stocks to Buy in June - The Globe and Mail

Jun 02, 2025
pulisher
May 31, 2025

The Next Stock I'm Buying? - The Globe and Mail

May 31, 2025
pulisher
May 29, 2025

NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times

May 29, 2025
pulisher
May 29, 2025

NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq

May 29, 2025
pulisher
May 29, 2025

First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews

May 29, 2025
pulisher
May 23, 2025

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance

May 23, 2025
pulisher
May 21, 2025

Here's How I'd Invest $10,000 Today - The Globe and Mail

May 21, 2025
pulisher
May 20, 2025

Grant Williamson appointed as Canada Leader for Willis - The Globe and Mail

May 20, 2025
pulisher
May 17, 2025

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’ - The Globe and Mail

May 17, 2025
pulisher
May 14, 2025

Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail

May 14, 2025
pulisher
May 13, 2025

Is Archer Aviation Stock (ACHR) a “Buy” Ahead of Q1 Earnings? - The Globe and Mail

May 13, 2025
pulisher
May 02, 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 02, 2025
pulisher
May 02, 2025

NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 02, 2025

NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks

May 02, 2025
pulisher
May 01, 2025

NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

NextCure, Inc. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan

May 01, 2025
pulisher
Apr 28, 2025

NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Apr 28, 2025

Nextcure Inc Stock (NXTC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Cap:     |  Volume (24h):